Reducing the cardiovascular consequences of diabetes mellitus

Diabetic Medicine

Volumn 15, Issue SUPPL. 4, 1998, Pages

  Passa, Philippe ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Coronary heart disease; Myocardial infarction; Primary prevention; Secondary prevention; Type 2 diabetes

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOLYTIC AGENT; GEMFIBROZIL; INSULIN; SIMVASTATIN;

BLOOD CLOT LYSIS; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR DISEASE; DIABETES CONTROL; HEALTH ECONOMICS; HEART INFARCTION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PRIMARY MEDICAL CARE; REVIEW; RISK ASSESSMENT;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; INCIDENCE; MYOCARDIAL INFARCTION;

EID: 0031793810     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1096-9136(1998120)15:4+3.3.co;2-e     Document Type: Article

References (21)

1. Stamler J, Vaccaro O, Neaton JD, Wentworth D. For the Multiple Risk Factor Intervention Trial Research Group. Diabetes, other risk factors and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-444.
2. Laakso M, Lehto S. Epidemiology of macrovascular disease in diabetes. Diabetes Reviews 1997; 5: 294-315.
3. University Group Diabetes Program. A study of the effects of hypoglycamic agents on vascular complications in patients with adult onset diabetes mortality results. Diabetes 1970; 19 (Suppl 2): 789-830.
4. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes. UKPDS 33. Lancet 1998; 352: 837-853.
5. Manson JE, Tosteson H, Ridker PM, et al. The primary prevention of myocardial infarction. N Engl J Med 1992; 326: 1406-1416.
6. UKPDS Group. Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes. UKPDS 38. BMJ 1998; 317: 703-713.
7. Fontbonne A. Relationship between diabetic dyslipoproteinemia and coronary heart disease risk in subjects with non-insulin-dependent diabetes mellitus. Diabetes Metab Rev 1991; 7: 179-189.
8. Koskinen P, Manttari M, Manninen V, Huttunen JK, Heinonen OP, Frick MH. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992; 15: 820-825.
9. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy I. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
10. ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. JAMA 1992; 268: 1292-1300.
11. Miettinen H, Lehto S, Salomaa V, et al. Impact of diabetes on mortality after the first myocardial infarction. Diabetes Care 1998; 21: 69-74.
12. Malmberg K, Lyden L, Efendic S, et al. Randomized trial of insulin glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI Study) effects on mortality at 1 year. J Am Coll Carcliol 1995; 26: 57-65.
13. Malmberg K for the DIGAMI Study Group. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. BMJ 1997; 314: 1512-1515.
14. ISIS-2. Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17 187 cases of suspected acute myocardial infarction. Lancet 1988; ii: 349-360.
15. Fibrinolytic Therapy Trialists' Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction : collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1,000 patients. Lancet 1994; 343: 311-322.
16. Malmberg K, Herlitz J, Hjalmarson A, Ryden J. Effects of metoprolol on mortality and late infarction in diabetes with suspected acute myocardial infarction. Retrospective data from two large studies. Eur Heart J 1989; 10: 423-428.
17. Zuanetti G, Latini R, Maggioni AP, Franzosi MG, Santoro L, Tognini G for the GISSI-3 investigators. Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction. Circulation 1997; 94: 4239-4245.
18. Kendall MJ, Lynch KP, Hjalmarson A, Kjekshus J. Beta-blockers and sudden cardiac death. Ann Intern Med 1995; 123: 358-367.
19. Mangano DT, Layug EL, Wallace A, Tateo I. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. N Engl J Med 1996; 335: 1713-1720.
20. The Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4 S). Lancet 1994; 344: 1383-1389.
21. Pyörälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgiersson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. Diabetes Care 1997; 20: 614-620.